The Effect of Coenzym Q10 on Doxorubicin-induced Cardiotoxicity in Non Hodgkin's Lymphoma Patients

Authors

  • Julita Melisa Dewi Otorhinolaryngologist - Head and Neck Surgery Departement, Faculty of Medicine Diponegoro University – Kariadi Hospital, Semarang, Indonesia
  • Dwi Antono Otorhinolaryngologist - Head and Neck Surgery Departement, Faculty of Medicine Diponegoro University – Kariadi Hospital, Semarang, Indonesia
  • Nur Iman Nugroho Otorhinolaryngologist - Head and Neck Surgery Departement, Faculty of Medicine Diponegoro University – Kariadi Hospital, Semarang, Indonesia
  • Willy Yusmawan Otorhinolaryngologist - Head and Neck Surgery Departement, Faculty of Medicine Diponegoro University – Kariadi Hospital, Semarang, Indonesia
  • Anna Mailasari Kusuma Dewi Otorhinolaryngologist - Head and Neck Surgery Departement, Faculty of Medicine Diponegoro University – Kariadi Hospital, Semarang, Indonesia

DOI:

https://doi.org/10.36408/mhjcm.v11i2.1089

Keywords:

Hodgkin's non lymphoma, Doxorubicin, Cardiotoxicity, Coenzym Q10

Abstract

BACKGROUND : Non-Hodgkin's Lymphoma is a primary malignancy in the Lymph Nodes and lymphoid tissue originating from B lymphocytes, T lymphocytes and Natural Killer (NK) cells. Therapy for Non-Hodgkin's Lymphoma chemotherapy can be given alone or combined with radioactive therapy. Doxorubicin is a chemotherapy drug used for lymphoma with side effects, one of which is cardiotoxic effects.

AIMS :  To prove that coenzyme Q10 can reduce the cardiotoxic effect of doxorubicin chemotherapy in non-Hodgkin's lymphoma patients

METHOD : Intervention study with a randomized pre and post test double blind control group design with 34 NHL patients undergoing chemotherapy. The treatment group received additional therapy with coenzyme Q10 300mg/day for 12 weeks while the controls received placebo. The cardiotoxic effects examined were assessed based on the results of Electrocardiography and Echocardiography.

RESULT :  The treatment group with coenzyme Q10 supplementation after the 4th chemotherapy showed a decrease in echocardiography results in 3 patients (18%) and in the control group 17 patients (100%). There was a significant difference in the echocardiography results of the treatment and control groups (p=0.001). There were no drug side effects in both groups

CONCLUSION : Coenzyme Q10 supplementation provides an improvement in the cardiotoxic effects of doxorubicin in non-Hodgkin's lymphoma patients, on echocardiography, but not on Electrocardiography.

Downloads

Download data is not yet available.

References

1. Kementrian Kesehatan Republik Indonesia. Non Hodgin Lymphoma Management guide. Jakarta; 2016.p.1-38.

2. Prayogo AA, Suryantoro SD, Savitri M, Hendrata WM, Wijaya AY, Pikir BS. High Sensitivity Troponin T as Complementary Modality for Determining Doxorubicin Regimen Cardiotoxicity in Non-Hodgkin Lymphoma Patients. Adv Pharm Bull. 2022;12(1):163-8. doi:10.341.

3. Blocks NE. B Cell Lymphomas, NCCN Evidences block. 2020 foll B. 1-4. 2020;

4. Maifitrianti, Sutandyo N, Andrajati R. Factor That Affect the Decline of Left Ventricular Ejection Fraction in Cancer Patients Treated With Doxorubicin At Dharmais. Media Farm. 2015;12:233–46.

5. Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S. Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol. 2019;96(2):219–32.

6. Kalyanaraman, Balaraman. “Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?.” Redox biology vol. 29 (2020): 101394. doi:10.1016/j.redox.2019.101394.

7. Purnamasidhi CAW, Suega K, Bakta IM. Association between lactate dehydrogenase levels to the response of non-hodgkin lymphoma in elderly patients who treated with first-line chemotherapy in sanglah general hospital. Open Access Maced J Med Sci. 2019;7(12):1984–6.

8. Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and heart failure. Circ Hear Fail. 2016;9(4):1–9.

9. Kusulistyo F, Suprihati S, Yusmawan W, Antono D, Budiarti R, Farokah F, et al. Pengaruh suplementasi koenzim q10 terhadap kadar laktat dehidrogenase penderita limfoma non-hodgkin yang menjalani kemoterapi di rsup dr.kariadi semarang. Medica Hosp J Clin Med. 2021;8(2):207–12.

10. Chung, W, B., Yi, J, E., Choi, Y, S., Park, C, S., Park, W, C., Song, B, J., & Youn H, J., 2013, Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with Breast Cancer. Journal of Breast Cancer.

11. Sorigue M, Mercadal S, Alonso S, Fernández-Álvarez R, Sancho JM. Is there a role for the international prognostic index in follicular lymphoma? Ann Hematol. 2018;97(4):713–5.

12. Siahaan IH, Tobing TC, Rosdiana N, Lubis B. Dampak kardiotoksik obat kemoterapi golongan antrasiklin. Sari Pediatr. 2016;9(2):151–6.

13. Kitakata H, Endo J, Ikura H, Moriyama H, Shirakawa K, Katsumata Y, et al. Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis. Int J Mol Sci. 2022;23(3).

14. Nebigil CG, Désaubry L. Updates in anthracycline-mediated cardiotoxicity. Front Pharmacol. 2018;9(NOV):1–13.

15. Santos DS dos, Goldenberg RC dos S. Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy. Cardiotoxicity. 2018;3–24.

16. Timm KN, Perera C, Ball V, Henry JA, Miller JJ, Kerr M, et al. Early detection of doxorubicin-induced cardiotoxicity in rats by its cardiac metabolic signature assessed with hyperpolarized MRI. Commun Biol. 2020;3(1):1–10.

17. Qahtani Abdullah, A., Balawi Hamed, A., Jowesim Fahad, A., Protective effect of coenzyme Q10 against doxorubicin-induced cardiotoxicity: scoping Review article, Saudi Pharmaceutical Journal (2023), doi: https://doi.org/10.1016/j.jsps.2023.101882. 2023;

 

Additional Files

Published

2024-07-31

How to Cite

1.
Dewi JM, Antono D, Nugroho NI, Yusmawan W, Dewi AMK. The Effect of Coenzym Q10 on Doxorubicin-induced Cardiotoxicity in Non Hodgkin’s Lymphoma Patients. Medica Hospitalia J. Clin. Med. [Internet]. 2024 Jul. 31 [cited 2024 Sep. 19];11(2):144-9. Available from: http://medicahospitalia.rskariadi.co.id/medicahospitalia/index.php/mh/article/view/1089

Issue

Vol. 11 No. 2 (2024): Med Hosp; July 2024

Section

Original Article

Citation Check

License

Copyright (c) 2024 Julita Melisa Dewi, Dwi Antono, Nur Iman Nugroho, Willy Yusmawan, Anna Mailasari Kusuma Dewi (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.